Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Aggressive Posterior Retinopathy of Prematurity
NCT07721298Completed
- Sponsor
- Ain Shams University
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial of ranibizumab in retinopathy of prematurity (ROP), sponsored by Ain Shams University. Primary endpoint: Disease regression following intravitreal ranibizumab at 1 week. Started Sep 2021; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT07721298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07721298.